These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 20222806

  • 21. Generation of retroviral packaging and producer cell lines for large-scale vector production with improved safety and titer.
    Dubensky TW, Sauter SL.
    Methods Mol Med; 2003; 76():309-30. PubMed ID: 12526171
    [No Abstract] [Full Text] [Related]

  • 22. Preloading potential of retroviral vectors is packaging cell clone dependent and centrifugation onto CH-296 ensures highest transduction efficiency.
    Sondergaard CS, Haldrup C, Beer C, Andersen B, Kohn DB, Pedersen L.
    Hum Gene Ther; 2009 Apr; 20(4):337-49. PubMed ID: 19281432
    [Abstract] [Full Text] [Related]

  • 23. Retargeting of retroviral integration sites for the predictable expression of transgenes and the analysis of cis-acting sequences.
    Schübeler D, Maass K, Bode J.
    Biochemistry; 1998 Aug 25; 37(34):11907-14. PubMed ID: 9718314
    [Abstract] [Full Text] [Related]

  • 24. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene.
    Persons DA, Mehaffey MG, Kaleko M, Nienhuis AW, Vanin EF.
    Blood Cells Mol Dis; 1998 Jun 25; 24(2):167-82. PubMed ID: 9642098
    [Abstract] [Full Text] [Related]

  • 25. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.
    Farson D, McGuinness R, Dull T, Limoli K, Lazar R, Jalali S, Reddy S, Pennathur-Das R, Broad D, Finer M.
    J Gene Med; 1999 Jun 25; 1(3):195-209. PubMed ID: 10738568
    [Abstract] [Full Text] [Related]

  • 26. Multiple modifications allow high-titer production of retroviral vectors carrying heterologous regulatory elements.
    Hlavaty J, Stracke A, Klein D, Salmons B, Günzburg WH, Renner M.
    J Virol; 2004 Feb 25; 78(3):1384-92. PubMed ID: 14722293
    [Abstract] [Full Text] [Related]

  • 27. Improved retroviral packaging lines derived from spleen necrosis virus.
    Martinez I, Dornburg R.
    Virology; 1995 Apr 01; 208(1):234-41. PubMed ID: 11831705
    [Abstract] [Full Text] [Related]

  • 28. Improved methods of retroviral vector transduction and production for gene therapy.
    Kotani H, Newton PB, Zhang S, Chiang YL, Otto E, Weaver L, Blaese RM, Anderson WF, McGarrity GJ.
    Hum Gene Ther; 1994 Jan 01; 5(1):19-28. PubMed ID: 8155767
    [Abstract] [Full Text] [Related]

  • 29. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines.
    Duisit G, Salvetti A, Moullier P, Cosset FL.
    Hum Gene Ther; 1999 Jan 20; 10(2):189-200. PubMed ID: 10022544
    [Abstract] [Full Text] [Related]

  • 30. Optimized conditions for the production of recombinant amphotropic retroviral vector preparations.
    Kaptein LC, Greijer AE, Valerio D, van Beusechem VW.
    Gene Ther; 1997 Feb 20; 4(2):172-6. PubMed ID: 9081708
    [Abstract] [Full Text] [Related]

  • 31. Retroviral vectors for the transduction of the PML-RARalpha fusion product of acute promyelocytic leukemia.
    Lavau C, Heard JM, Danos O, Dejean A.
    Exp Hematol; 1996 Mar 20; 24(4):544-51. PubMed ID: 8608805
    [Abstract] [Full Text] [Related]

  • 32. Production of minigene-containing retroviral vectors using an alphavirus/retrovirus hybrid vector system.
    Wahlfors JJ, Morgan RA.
    Hum Gene Ther; 1999 May 01; 10(7):1197-206. PubMed ID: 10340551
    [Abstract] [Full Text] [Related]

  • 33. A convenient method for positive selection of retroviral producing cells generating vectors devoid of selectable markers.
    Xu L, Tsuji K, Mostowski H, Otsu M, Candotti F, Rosenberg AS.
    J Virol Methods; 2004 Jun 01; 118(1):61-7. PubMed ID: 15158069
    [Abstract] [Full Text] [Related]

  • 34. Comparison of gene-trapping efficiency between retroviral and lentiviral vectors in mouse embryonic stem cells.
    Yamaguchi T, Morikawa A, Miyoshi H.
    Biochem Biophys Res Commun; 2012 Aug 24; 425(2):297-303. PubMed ID: 22842569
    [Abstract] [Full Text] [Related]

  • 35. Correction of the enzyme deficiency in hematopoietic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol.
    Xu L, Stahl SK, Dave HP, Schiffmann R, Correll PH, Kessler S, Karlsson S.
    Exp Hematol; 1994 Feb 24; 22(2):223-30. PubMed ID: 8299741
    [Abstract] [Full Text] [Related]

  • 36. Expression of human glucocerebrosidase in murine macrophages: identification of efficient retroviral vectors.
    Freas-Lutz DL, Correll PH, Dougherty SF, Xu L, Pluznik DH, Karlsson S.
    Exp Hematol; 1994 Aug 24; 22(9):857-65. PubMed ID: 8062885
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Using RT-prone recombination to promote re-building of complete retroviral vectors from two defective precursors: low efficiency and sequence specificities.
    Bru T, Galetto R, Piver E, Collin C, Negroni M, Pagès JC.
    J Virol Methods; 2007 Jun 24; 142(1-2):118-26. PubMed ID: 17336399
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.